Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1979 Jun;69(6):566–573. doi: 10.2105/ajph.69.6.566

Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.

P M Layde, S D von Allmen, G P Oakley Jr
PMCID: PMC1618991  PMID: 87134

Abstract

The prenatal detection of fetal neural tube defects (NTD) is now possible by means of a multi-tiered program utilizing maternal serum alpha-fetoprotein (MSAFP) screening coupled with ultrasonography and amniocentesis where indicated. This paper considers the economic consequences of screening for fetal NTD a theoretical cohort of 100,000 pregnant women at risk of having an affected fetus who would elect to terminate their pregnancies if an affected fetus were found. The cost of the program was balanced against the benefits of the program, such as the averted costs of institutionalization, medical care, and the like. The total cost of the program to screen 100,000 such women was calculated to be $2,047,780, or slightly over $20 per woman screened, while the total economic benefits exceeded $4,000,000.

Full text

PDF
566

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arney W. R., Trescher W. H. Trends in attitudes toward abortion, 1972-1975. Fam Plann Perspect. 1976 May-Jun;8(3):117–124. [PubMed] [Google Scholar]
  2. Douglas D. L. Gastroschisis and alpha-fetoprotein. Lancet. 1977 Jan 1;1(8001):42–42. doi: 10.1016/s0140-6736(77)91676-2. [DOI] [PubMed] [Google Scholar]
  3. Hagard S., Carter F., Milne R. G. Screening for spina bifida cystica. A cost-benefit analysis. Br J Prev Soc Med. 1976 Mar;30(1):40–53. doi: 10.1136/jech.30.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Laurence K. M., Tew B. J. Natural history of spina bifida cystica and cranium bifidum cysticum. Major central nervous system malformations in South Wales. IV. Arch Dis Child. 1971 Apr;46(246):127–138. doi: 10.1136/adc.46.246.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Leck I. Causation of neural tube defects: clues from epidemiology. Br Med Bull. 1974 May;30(2):158–163. doi: 10.1093/oxfordjournals.bmb.a071187. [DOI] [PubMed] [Google Scholar]
  6. Lightowler C. D. Meningomyelocele: the price of treatment. Br Med J. 1971 May 15;2(5758):385–387. doi: 10.1136/bmj.2.5758.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mamunes P. Newborn screening for metabolic disorders. Clin Perinatol. 1976 Mar;3(1):231–250. [PubMed] [Google Scholar]
  8. Milunsky A., Alpert E. Prenatal diagnosis of neural tube defects. I. Problems and pitfalls: analysis of 2495 cases using the alpha-fetoprotein assay. Obstet Gynecol. 1976 Jul;48(1):1–5. [PubMed] [Google Scholar]
  9. Milunsky A., Alpert E. Prenatal diagnosis of neural tube defects. II. Analysis of false positive and false negative alpha-fetoprotein results. Obstet Gynecol. 1976 Jul;48(1):6–12. [PubMed] [Google Scholar]
  10. Reid R. Spina bifida: the fate of the untreated. Hastings Cent Rep. 1977 Aug;7(4):16–19. [PubMed] [Google Scholar]
  11. Seller M. J. Amniotic fluid alpha-fetoprotein and Turner's syndrome. Lancet. 1977 Apr 30;1(8018):955–956. doi: 10.1016/s0140-6736(77)92255-3. [DOI] [PubMed] [Google Scholar]
  12. Stark G. D., Drummond M. Results of selective early operation in myelomeningocele. Arch Dis Child. 1973 Sep;48(9):676–683. doi: 10.1136/adc.48.9.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wald N. J., Cuckle H., Brock J. H., Peto R., Polani P. E., Woodford F. P. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet. 1977 Jun 25;1(8026):1323–1332. [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES